Title : Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.

Pub. Date : 2012 Jun

PMID : 22421369






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 ZRBA1 is a quinazoline-based molecule termed "combi-molecule" designed to block the epidermal growth factor receptor (EGFR) and further degrade to FD105, an EGFR inhibitor plus a DNA-alkylating agent. Quinazolines epidermal growth factor receptor Homo sapiens
2 ZRBA1 is a quinazoline-based molecule termed "combi-molecule" designed to block the epidermal growth factor receptor (EGFR) and further degrade to FD105, an EGFR inhibitor plus a DNA-alkylating agent. Quinazolines epidermal growth factor receptor Homo sapiens
3 ZRBA1 is a quinazoline-based molecule termed "combi-molecule" designed to block the epidermal growth factor receptor (EGFR) and further degrade to FD105, an EGFR inhibitor plus a DNA-alkylating agent. Quinazolines epidermal growth factor receptor Homo sapiens
4 This study conclusively demonstrated that designing molecules as prodrugs of high levels of quinazoline inhibitors of EGFR and bifunctional DNA cross-linking species is a valid strategy to enhance the potency of mixed EGFR-DNA-targeting combi-molecules. Quinazolines epidermal growth factor receptor Homo sapiens
5 This study conclusively demonstrated that designing molecules as prodrugs of high levels of quinazoline inhibitors of EGFR and bifunctional DNA cross-linking species is a valid strategy to enhance the potency of mixed EGFR-DNA-targeting combi-molecules. Quinazolines epidermal growth factor receptor Homo sapiens